Phenox — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Phenox is a privately held, commercial-stage medical device company specializing in interventional neurology. It has established a robust portfolio of products for ischemic stroke (thrombectomy) and hemorrhagic stroke (aneurysm treatment), with a strong focus on evidence-based medicine through rigorous clinical trials like COATING and PROST. The company is actively expanding its global commercial footprint and continues to innovate within the high-growth neurovascular market, positioning itself as a key player alongside larger medtech corporations.

StrokeNeurovascular DiseasesIntracranial Aneurysm

Technology Platform

Advanced mechanical engineering of neurovascular implants, including thrombectomy devices, flow diverters, and aneurysm implants. Proprietary Hydrophilic Polymer Coating (HPC) technology to reduce device thrombogenicity.

Opportunities

The global shift towards minimally invasive stroke treatment and an aging population drive significant growth in the neurovascular device market.

Phenox's clinically differentiated products, like the HPC-coated flow diverter proven for single antiplatelet therapy, allow it to capture share in specialized niches.

Strategic expansion into new geographic regions presents a major avenue for increasing revenue.

Risk Factors

Phenox faces intense competition from large, well-resourced medical device conglomerates with dominant market positions.

Regulatory pathways in key markets like the U.S.

and China are complex and can delay product launches.

The company's concentrated focus on neurovascular devices creates dependency on this single, albeit large, therapeutic area.

Competitive Landscape

Phenox competes in the highly competitive neurovascular intervention market against global giants like Medtronic, Stryker Neurovascular, Johnson & Johnson (Cerenovus), and MicroVention (Terumo). Its strategy is to compete through technological innovation, specialized device design, and high-level clinical evidence, rather than scale, targeting specific clinical needs unmet by broader portfolios.

More companies in Neuroscience & CNS →More companies in Germany →